Key points from article :
Swedish biotech company Epigenica has raised $2.2 million in new funding to accelerate the commercialization of its EpiFinder platform—a high-throughput technology designed to precisely and efficiently measure epigenetic changes across a range of sample types. Published this week, the announcement underscores the company's growing role in the expanding field of epigenomics, particularly in areas like longevity, drug development, and precision medicine. Epigenica’s CEO, Dr. Mohamad Takwa, emphasized the platform’s potential to reveal how aging affects gene expression, enabling the discovery of biomarkers and therapeutic targets for age-related diseases such as cancer, neurodegeneration, and cardiovascular disorders.
Epigenetics involves chemical modifications to DNA and proteins—such as DNA methylation and histone modifications—that influence gene activity without altering the genetic code itself. While this field holds enormous promise, existing technologies often struggle with low throughput, high costs, and incomplete data. Epigenica’s EpiFinder Genome overcomes these limitations by combining multiple epigenetic marker analyses in a single, scalable workflow, allowing researchers to generate 192 genome-wide profiles simultaneously across up to eight markers and 24 samples.
The technology integrates seamlessly with a wide range of biological materials, from cultured cells to tissue samples, enabling more robust and replicable data for both academic and commercial research. Epigenica is also developing new kits to support blood-based epigenomics and high-throughput screening, broadening the platform’s clinical and diagnostic utility. These innovations position the company at the forefront of the multi-omics revolution, which combines genomics, transcriptomics, proteomics, and metabolomics to better understand complex biological systems.
Backed by investors including Voima Ventures, Navigare Ventures, and Almi Invest, Epigenica plans to scale up operations and expand in the U.S. and beyond. As demand for precision epigenetic tools grows, Epigenica is poised to play a pivotal role in translating epigenetic insights into real-world health solutions, particularly in the emerging field of longevity research.
